Antibodies against metal chelates
- PMID: 3927170
- DOI: 10.1038/316265a0
Antibodies against metal chelates
Abstract
Because monoclonal antibodies can recognize and bind to specific groups of atoms such as tumour antigens, they have promise for use in vivo as carriers of radionuclides, drugs or other appended molecules for diagnosis and treatment of disease. Attachment of metal ions to antibodies by means of bifunctional chelating agents can add the diverse nuclear, physical and chemical properties of the metallic elements to these specific binding proteins (ref. 4 and refs therein). With the ultimate aim of engineering probe-binding properties into the antibodies themselves, we have now prepared monoclonal antibodies against the EDTA chelate of indium. These antibodies show a remarkable preference for indium chelates; changing to another metal such as scandium or gallium can decrease the antibody-binding constant by more than three orders of magnitude. These antibodies also introduce a new degree of control over the biological distributions of chelated radionuclides, markedly altering their uptake in tumours and normal organs.
Similar articles
-
How the anti-(metal chelate) antibody CHA255 is specific for the metal ion of its antigen: X-ray structures for two Fab'/hapten complexes with different metals in the chelate.Biochemistry. 1993 Oct 19;32(41):10950-9. doi: 10.1021/bi00092a004. Biochemistry. 1993. PMID: 8218161
-
Monoclonal antibodies that recognize minimal differences in the three-dimensional structures of metal-chelate complexes.Bioconjug Chem. 2002 May-Jun;13(3):408-15. doi: 10.1021/bc0155418. Bioconjug Chem. 2002. PMID: 12009928
-
Purification and characterization of a chimeric bifunctional antibody specific for human carcinoembryonic antigen and indium-benzyl-EDTA.Protein Expr Purif. 1991 Feb;2(1):75-82. doi: 10.1016/1046-5928(91)90014-a. Protein Expr Purif. 1991. PMID: 1821776
-
Labeling of monoclonal antibodies with radionuclides.Semin Nucl Med. 1989 Jul;19(3):187-201. doi: 10.1016/s0001-2998(89)80013-3. Semin Nucl Med. 1989. PMID: 2503873 Review.
-
Pharmacokinetics and biodistribution of genetically-engineered antibodies.Q J Nucl Med. 1998 Dec;42(4):225-41. Q J Nucl Med. 1998. PMID: 9973838 Review.
Cited by
-
Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer.J Nucl Med. 2017 Nov;58(11):1735-1742. doi: 10.2967/jnumed.117.193250. Epub 2017 Jul 13. J Nucl Med. 2017. PMID: 28705917 Free PMC article.
-
Regulating the reactivity of black phosphorus via protective chemistry.Sci Adv. 2020 Nov 11;6(46):eabb4359. doi: 10.1126/sciadv.abb4359. Print 2020 Nov. Sci Adv. 2020. PMID: 33177081 Free PMC article.
-
Phosphorylation-induced signal propagation in the response regulator ntrC.J Bacteriol. 2000 Sep;182(18):5188-95. doi: 10.1128/JB.182.18.5188-5195.2000. J Bacteriol. 2000. PMID: 10960104 Free PMC article.
-
A semiempirical model of tumor pretargeting.Bioconjug Chem. 2008 Nov 19;19(11):2095-104. doi: 10.1021/bc8002748. Bioconjug Chem. 2008. PMID: 18839978 Free PMC article. Review.
-
Radioimmunotherapy: no news from the newcomer.J Cancer Res Clin Oncol. 1994;120(3):121-30. doi: 10.1007/BF01202189. J Cancer Res Clin Oncol. 1994. PMID: 8263007 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials